Oncotelic Therapeutics (OTCQB: OTLC) was featured in a NetworkNewsAudio audio press release focused on emerging opportunities in central nervous system drug delivery, highlighting the challenges posed by the blood-brain barrier and the company’s efforts to advance technologies designed to overcome those limitations. The editorial also noted Oncotelic’s recent strategic monetization agreement with Lunai Bioworks involving its N2B delivery system, supporting initiatives in biodefense and Alzheimer’s disease treatment.
NOTE TO INVESTORS: The latest news and updates relating to OTLC are available in the company’s newsroom at https://nnw.fm/OTLC
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer